<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

 Gregory G. Schwartz, MD, PhD, chief of the cardiology section at Rocky Mountain Regional VA Medical Center and professor of medicine at the University of Colorado School of Medicine in Aurora, Colorado, is leading the VA-IMPACT trial. Despite metformin's long history and widespread use, he said his study is the first placebo-controlled cardiovascular outcomes trial of the drug.